Index

Catalog of every page in the wiki. Updated on every ingest. Organized by category — each category also has its own landing page with the same list plus a short blurb per page.

Overview & meta

• Overview — the evolving synthesis / thesis of the wiki
• Log — chronological record of ingests, queries, and lints

Sources

• Azhar 2021 - SCANDIV 5-Year Outcomes — SCANDIV RCT 5-year follow-up: lavage vs. resection for perforated purulent diverticulitis
• Vennix 2015 - Ladies Trial LOLA — Ladies trial (LOLA group): lavage vs. sigmoidectomy, stopped early for safety
• Boublikova 2023 - TNT in Rectal Cancer Review — review of total neoadjuvant therapy for locally advanced rectal cancer, synthesizing 4 phase III RCTs
• Hoehn 2021 - Appendiceal Neoplasms — review of all 5 appendiceal neoplasm subtypes, staging, and CRS/HIPEC controversies
• Lambrichts 2019 - LADIES DIVA Trial — LADIES DIVA arm: Hartmann’s vs. primary anastomosis for Hinchey III/IV diverticulitis
• Sabiston Ch52 - Diverticular Disease, Obstruction & Pseudo-Obstruction — textbook reference (chunk 1 of the “Colon and Rectum” chapter): uncomplicated diverticulitis, elective surgery timing, large bowel obstruction, Ogilvie syndrome
• Sabiston Ch52 - Inflammatory Bowel Disease — textbook reference (chunk 2 of the “Colon and Rectum” chapter): UC and Crohn’s epidemiology, diagnosis, medical treatment, surgical indications
• Sabiston Ch52 - Infectious & Ischemic Colitis — textbook reference (chunk 3 of the “Colon and Rectum” chapter): C. difficile and other infectious colitis, ischemic colitis
• Sabiston Ch52 - Colorectal Neoplasia & Colon Cancer Surgery — textbook reference (chunk 4 of the “Colon and Rectum” chapter): CRC genetics, polyps, hereditary syndromes, staging, colon cancer surgery, obstructing colon cancer
• Sabiston Ch52 - Rectal Cancer Surgery — textbook reference (chunk 5 of the “Colon and Rectum” chapter): rectal cancer staging/TME history, LAR, sphincter-sparing surgery, APR, anastomotic complications, LARS, adjuvant chemotherapy
• Sabiston Ch52 - Pelvic Floor Disorders & Constipation — textbook reference (chunk 6, final chunk, of the “Colon and Rectum” chapter): anorectal physiology testing, rectal prolapse, SRUS, rectocele, constipation
• Sabiston Ch50 - Small Bowel Anatomy, Physiology, Obstruction & Crohn Disease — textbook reference (chunk 1 of the “Small Bowel” chapter): small intestine anatomy/physiology, small bowel obstruction, Crohn disease (full small-bowel-focused treatment)
• Sabiston Ch50 - Infectious Enteritis & Small Bowel Neoplasms — textbook reference (chunk 2 of the “Small Bowel” chapter): rest of Crohn disease, typhoid enteritis, immunocompromised-host enteritis, small bowel neoplasms (NETs, adenocarcinoma, GIST, lymphoma, benign tumors)
• Sabiston Ch50 - Diverticular Disease & Miscellaneous Problems — textbook reference (chunk 3, final chunk, of the “Small Bowel” chapter): duodenal/jejunoileal/Meckel diverticula, small bowel ulcerations, foreign bodies, enterocutaneous fistula, pneumatosis intestinalis, blind loop syndrome, radiation enteritis, short bowel syndrome, SMA syndrome. Completes the wiki’s original planned ingest list.
• ACG 2025 - Ulcerative Colitis Guideline — society guideline (Am J Gastroenterol 2025): full medical-management and ASUC algorithm for UC. Filed in guidelines-trials/ (see Guidelines & Trials) since it’s a guideline entity, not a single-paper source — listed here too since it functions as this ingest’s source document.
• AGA 2024 - Moderate-to-Severe UC Pharmacotherapy Guideline — society living guideline (Gastroenterology 2024): NMA-based efficacy positioning, combination therapy, de-escalation, step therapy, pregnancy. Filed in guidelines-trials/.
• BSG 2025 - IBD Guidelines (Adults) — society guideline (Gut 2025), covers both UC and Crohn’s plus cross-cutting IBD topics. First primary-guideline source for Crohn’s medical/surgical management. Filed in guidelines-trials/.
• Bahadoer 2021 - RAPIDO Trial — RAPIDO phase 3 RCT: SCRT+chemo (TNT) vs. standard CRT in high-risk LARC. Reduced distant metastases, no OS benefit, numerically worse locoregional control at 3 years — confirmed statistically significant at 5.6 years, see Dijkstra 2023 - RAPIDO 5-Year Locoregional Failure.
• Conroy 2024 - PRODIGE 23 Long-Term Results — PRODIGE 23 7-year follow-up: chemotherapy-first TNT vs. standard CRT. First rectal-cancer TNT trial with a mature OS benefit, no locoregional trade-off.
• Jin 2022 - STELLAR Trial — STELLAR phase 3 RCT: SCRT-based TNT vs. standard CRT. Noninferior DFS, no locoregional trade-off (unlike RAPIDO), roughly double the acute toxicity.
• Schrag 2023 - PROSPECT Trial — PROSPECT phase 2/3 RCT: FOLFOX with selective CRT vs. routine CRT in lower-risk, sphincter-sparing-eligible LARC — a radiation-omission trial, distinct from TNT.
• Caplin 2014 - CLARINET Trial — CLARINET phase 3 RCT: lanreotide vs. placebo in nonfunctioning enteropancreatic NETs. Significantly prolonged PFS.
• Rinke 2009 - PROMID Trial — PROMID phase IIIB RCT: octreotide LAR vs. placebo in midgut NETs. First placebo-controlled antiproliferative SSA evidence.
• Strosberg 2017 - NETTER-1 Trial — NETTER-1 phase 3 RCT: 177Lu-Dotatate (PRRT) vs. high-dose octreotide in SSA-progressive midgut NETs. 79% lower risk of progression/death.
• Yao 2016 - RADIANT-4 Trial — RADIANT-4 phase 3 RCT: everolimus vs. placebo in advanced non-functional lung/GI NETs. Median PFS 11.0 vs. 3.9 months.
• Ciseł 2019 - POLISH II Long-Term Results — POLISH II long-term follow-up: short-course RT + consolidation chemo vs. long-course chemoradiation in cT4/fixed-cT3 rectal cancer. Neutral trial — no efficacy difference in either direction.
• Dijkstra 2023 - RAPIDO 5-Year Locoregional Failure — RAPIDO 5.6-year follow-up. Confirms a statistically significant increase in locoregional recurrence with TNT, resolving this wiki’s previously-unresolved cross-trial disagreement.
• Quénet 2021 - PRODIGE 7 Trial — PRODIGE 7 phase 3 RCT: CRS+HIPEC vs. CRS alone for colorectal peritoneal metastases. No OS/RFS benefit from HIPEC; more morbidity.
• Brouquet 2020 - GRECCAR16 Trial Protocol — NORAD01-GRECCAR16 protocol (no results yet): FOLFIRINOX replacing radiotherapy vs. standard CRT in CRM-negative resectable LARC.
• Alvarez 2024 - JANUS Trial Protocol — Janus trial protocol (no results yet, accruing): triplet vs. doublet consolidation chemotherapy for clinical complete response/organ preservation.

(see Sources for full list)

Conditions

• Diverticulitis — Hinchey classification; lavage vs. resection debate, cross-trial synthesis; uncomplicated diverticulitis, elective surgery timing, special populations
• Rectal Cancer — preoperative evaluation, staging, TME/CRM/downstaging history, survival, adjuvant chemotherapy by stage; see also Total Neoadjuvant Therapy (TNT)
• Appendiceal Neoplasms — 5 subtypes (MAN/PMP, NEN, GCA, colonic-type, signet ring), AJCC staging, management by subtype
• Large Bowel Obstruction — mechanical/functional etiologies, closed-loop obstruction, treatment by cause
• Colonic Pseudo-Obstruction (Ogilvie Syndrome) — epidemiology, escalating management (neostigmine, colonoscopic decompression, surgery)
• Inflammatory Bowel Disease — shared UC/Crohn’s epidemiology, classification, clinical features, diagnosis, medical treatment
• Ulcerative Colitis — disease severity/monitoring, full medical management and advanced-therapy roster, acute severe UC (ASUC) algorithm, surgical indications and options (IPAA, ileorectal anastomosis, continent ileostomy)
• Crohn Disease — history, epidemiology, etiology/genetics, pathology, clinical features, diagnosis, medical therapy ladder plus primary-guideline-sourced advanced therapy/TDM/post-surgical management, and surgical treatment (colonic and small-bowel, incl. strictureplasty)
• Infectious Colitis — C. difficile (epidemiology, treatment ladder, FMT, surgery) and other enteric pathogens
• Ischemic Colitis — watershed anatomy, diagnosis, conservative vs. surgical treatment
• Colorectal Polyps — nonneoplastic/serrated/neoplastic polyps, malignant polyp management, postpolypectomy surveillance
• Hereditary Colorectal Cancer Syndromes — overview; see Familial Adenomatous Polyposis (FAP), Lynch Syndrome, Hamartomatous Polyposis Syndromes
• Obstructing Colon Cancer — presentation, diagnosis, management by side
• Low Anterior Resection Syndrome (LARS) — definition, causes, prevention, treatment
• Rectal Prolapse (Procidentia) — anatomy, symptoms, diagnosis, nonoperative management
• Solitary Rectal Ulcer Syndrome (SRUS) — pathophysiology, symptoms, diagnosis, management
• Rectocele — risk factors, symptoms, diagnosis, surgical repair
• Constipation — Rome IV criteria, slow transit constipation, surgical options
• Small Bowel Obstruction — causes (adhesions/neoplasms/hernias/Crohn’s), simple vs. strangulating, diagnosis, treatment ladder, recurrent/postoperative obstruction, ileus
• Typhoid Enteritis — Salmonella typhi, diagnosis, treatment, hemorrhage/perforation
• Enteritis in the Immunocompromised Host — protozoal/bacterial/mycobacterial/viral/fungal enteric pathogens in AIDS and transplant patients
• Small Bowel Neoplasms — overview: epidemiology, risk factors, clinical manifestations, diagnosis, benign tumors (stromal, adenomas incl. FAP/Spigelman, lipomas, Peutz-Jeghers, hemangiomas), lymphoma; see also Small Bowel Neuroendocrine Tumors (NETs), Small Bowel Adenocarcinoma, Gastrointestinal Stromal Tumors (GIST)
• Small Bowel Neuroendocrine Tumors (NETs) — origin/classification, carcinoid syndrome, diagnosis (CgA/5-HIAA/DOTATATE PET), surgical and medical treatment (SSAs, everolimus, PRRT)
• Small Bowel Adenocarcinoma — epidemiology, diagnosis, surgical treatment by location, adjuvant chemotherapy, prognosis
• Gastrointestinal Stromal Tumors (GIST) — KIT/CD117, mitotic index risk stratification, imatinib-based treatment algorithm
• Small Bowel Diverticular Disease — true vs. false diverticula overview; see Duodenal Diverticula, Jejunal and Ileal Diverticula, Meckel Diverticulum
• Small Bowel Ulcerations — causal taxonomy, NSAID enteropathy
• Ingested Foreign Bodies — observation vs. laparotomy decision-making
• Enterocutaneous Fistula — three-phase management (stabilization, staging, definitive surgery)
• Pneumatosis Intestinalis — primary vs. secondary, “radiographic finding not a diagnosis”
• Blind Loop Syndrome — bacterial overgrowth, Schilling test, antibiotics
• Radiation Enteritis — acute vs. chronic, prevention strategies, treatment
• Short Bowel Syndrome — adaptive hyperplasia, early/late phase management, teduglutide, intestinal transplantation
• Vascular Compression of the Duodenum (SMA Syndrome) — Wilkie syndrome, diagnosis, treatment

(see Conditions for full list)

Procedures

• Ileal Pouch-Anal Anastomosis (IPAA) — J-pouch construction, technique, complications, functional outcomes
• Colon Cancer Resection — oncologic principles and technique by tumor location
• Local Excision of Rectal Neoplasms — endoscopic and transanal excision techniques
• Total Mesorectal Excision (TME) & Sphincter-Sparing Resection — LAR/TME, coloanal anastomosis, taTME
• Abdominoperineal Resection (APR) — indications, technique, recurrence rate vs. LAR
• Rectal Prolapse Repair — abdominal vs. perineal approaches

(see Procedures for full list)

Concepts

• Total Neoadjuvant Therapy (TNT) — neoadjuvant chemo+RT before surgery for locally advanced rectal cancer; efficacy, indications, regimens, NOM
• Cytoreductive Surgery and HIPEC — CRS/HIPEC for peritoneal surface malignancy; PCI/CC scoring, outcomes, controversies
• Colorectal Cancer Molecular Pathways — chromosomal instability, CIMP, MSI mutator pathway, EMT, CMS1-4
• Colorectal Cancer Staging (TNM) — TNM/AJCC framework, prognostic factors
• Colorectal Anastomotic Complications — leak, necrosis, bleeding, twisting, strictures
• Anorectal Physiology Testing — manometry, defecography, colonic transit study
• Small Intestine Anatomy & Physiology — embryology, anatomy, digestion/absorption, motility, endocrine and immune function

(see Concepts for full list)

Guidelines & Trials

• SCANDIV Trial — landmark RCT, lavage vs. resection for perforated diverticulitis
• Ladies Trial — landmark RCT, both arms ingested: LOLA (lavage vs. resection) and DIVA (Hartmann’s vs. primary anastomosis)
• ACG 2025 - Ulcerative Colitis Guideline — 2025 ACG society guideline: full UC medical management, advanced-therapy roster, and ASUC algorithm
• AGA 2024 - Moderate-to-Severe UC Pharmacotherapy Guideline — 2024 AGA living guideline: NMA-based efficacy positioning, combination therapy, de-escalation, step therapy, pregnancy
• BSG 2025 - IBD Guidelines (Adults) — 2025 BSG guideline covering both UC and Crohn’s plus cross-cutting topics; first primary-guideline source for Crohn’s management

(see Guidelines & Trials for full list)